BXRXQ
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2023 Q3 | -0.30 | $0 | -$2M |
| 2023 Q2 | -1.51 | $0 | -$3M |
| 2023 Q1 | 4.91 | $0 | -$5M |
| 2022 Q4 | -12.33 | $310,000 | -$4M |
| 2022 Q3 | -98.70 | $238,000 | -$4M |
| 2022 Q2 | -41.95 | $300,000 | -$7M |
| 2022 Q1 | -126.87 | $422,000 | -$13M |
| 2021 Q4 | 446.40 | $400,000 | -$13M |